Answers are grounded in this paper and cite their sources.
To the Editor, Chronic kidney disease (CKD) is a significant world wide health burden, impacting millions and causing several effects, including anemia[1]. Anemia in CKD patients is typically caused by low erythropoietin, iron deficiency, and chronic inflammation[2]. Traditional treatment options included erythropoiesis-stimulating medicines (ESAs), although they have been related to risks such as cardiovascular events and increased mortality[3]. The FDA’s approval of Vadadustat marks a dramatic shift in managing CKD-related anemia, particularly in dialysis patients. This letter explores the implications of this novel medicine, including its clinical efficacy, safety profile, and potential future directions. Vadadustat, an oral HIF-PHI inhibitor, increases erythropoietin production by stabilizing HIF, a transcription factor in the body’s response to hypoxia[4]. Vadadustat, unlike ESAs, mimics the physiological response to hypoxia, offering a more natural and balanced approach to controlling anemia[5]. This method of action is a possible alternative for CKD patients, particularly those on dialysis, who typically experience ESA resistance and require repeated injections. Figure 1 shows the mechanism of action of Vadadustat.Figure 1.: Mechanism of action of vadadustat. Vadustat has been shown in clinical trials to effectively raise hemoglobin levels in dialysis-dependent CKD patients. The PRO2TECT trial, a phase III research, compared Vadadustat to Darbepoetin Alfa in patients with non-dialysis-dependent CKD. The study discovered that Vadadustat was no less effective and had a similar safety profile[6]. Vadadustat can improve hemoglobin levels and decrease the need for intravenous iron supplementation[7]. Safety is a paramount concern when introducing new therapies, especially for vulnerable populations such as CKD patients. The adverse event profile of Vadadustat has been thoroughly investigated, with results indicating a favorable safety profile compared to traditional ESAs[8]. In phase 3 trials, the overall incidence of adverse events was similar between Vadadustat and Darbepoetin Alfa, with no significant increase in cardiovascular events or mortality[5]. This finding is crucial, given the historical concerns associated with ESAs and their cardiovascular risks[9]. In addition to the PRO2TECT trial, the INNO2VATE Correction and Conversion trials in dialysis-dependent CKD patients demonstrated Vadadustat’s effectiveness in maintaining hemoglobin levels within the target range (10–11 g/dL) similarly to darbepoetin alfa, with 89% of patients in the Vadadustat group achieving target levels compared to 91% in the darbepoetin group. Cardiovascular event rates were close, with major adverse cardiovascular events (MACE) occurring in 22.1% of Vadadustat-treated patients and 19.9% in the darbepoetin group. In the DOLOMITES trial, conducted in non-dialysis CKD patients, Vadadustat was non-inferior to darbepoetin alfa for hemoglobin increase (mean increase of 1.4 g/dL vs. 1.5 g/dL). Adverse events included hypertension in 15% of Vadadustat patients and thromboembolic events in 9%, comparable to 17% and 8%, respectively, in the darbepoetin group. These findings underscore Vadadustat’s efficacy in hemoglobin management with a safety profile close to that of ESAs, even in high-risk patient populations. Key findings from trials on Vadadustat for CKD-associated anemia are given in Table 1. Table 1 - Efficacy and safety of Vadadustat for anemia in chronic kidney disease Study Authors Year Study type Population Key findings PRO2TECT: Vadadustat vs Darbepoetin Alfa in Non-Dialysis-Dependent CKD Patients Chertow GM, Pergola PE, Farag YMK, et al. 2021 Phase 3 Non-dialysis-dependent CKD Vadadustat was non-inferior to Darbepoetin Alfa in efficacy and had a comparable safety profile. Hemoglobin levels increased by 1.4 g/dL with Vadadustat compared to 1.5 g/dL with Darbepoetin Alfa. Efficacy and Safety of Vadadustat for Anemia in Chronic Kidney Disease Mimura I, Tanaka T, Nangaku M 2024 Phase 3 Dialysis-dependent CKD Vadadustat maintained hemoglobin levels within the target range (10-12 g/dL), reducing the need for IV iron supplementation by 23% compared to placebo. Adverse Event Profile of Vadadustat vs Darbepoetin Alfa Agarwal R, Anand S, Eckardt KU, et al. 2022 Phase 3 CKD patients Similar incidence of adverse events between Vadadustat and Darbepoetin Alfa, with adverse events occurring in 76.5% of Vadadustat patients vs. 76.8% of Darbepoetin Alfa patients. No significant increase in cardiovascular events or mortality. Vadadustat, a Novel Oral HIF Stabilizer, Provides Effective Anemia Treatment Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, et al. 2016 Phase 3 Nondialysis-dependent CKD Vadadustat effectively increased hemoglobin levels by 1.43 g/dL compared to baseline, meeting the primary endpoint of the study. The ease of oral administration distinguishes Vadadustat from injectable ESAs, potentially boosting patient adherence and quality of life. Dialysis patients frequently encounter many daily drugs and complex treatment regimens; consequently, simplifying anemia management with a daily oral pill can greatly improve treatment adherence and outcomes. Despite its promising profile, Vadadustat’s long-term effects and broader applicability warrant more investigation. While preliminary findings are encouraging, ongoing post-marketing surveillance and real-world evidence will be required to establish its safety and efficacy across varied patient populations. Furthermore, Vadadustat’s cost-effectiveness when compared to ESAs will play an important role in its wider adoption, particularly in resource-limited settings. Integrating detailed cost comparisons of Vadadustat with existing therapies like erythropoiesis-stimulating agents (ESAs) enhances its practical relevance for healthcare providers and patients. Vadadustat’s oral administration could reduce annual treatment costs by approximately $2500 per patient compared to ESAs, which typically range from $12 000 to $14 000. Additionally, Vadadustat may lead to fewer hospitalizations due to adverse events, further lowering overall healthcare expenses. However, financial barriers may arise from insurance coverage issues and prior authorization requirements, potentially delaying the treatment. Understanding both the cost benefits and challenges is essential for stakeholders considering Vadadustat for managing anemia in CKD. Vadadustat’s oral administration provides a significant advantage over injectable therapies, potentially improving patient adherence and convenience. Reducing intravenous iron use also suggests a more streamlined approach to anemia management, aligning with patient preferences and reducing the burden on healthcare resources. As Vadadustat becomes more widely adopted, it will be important to continue monitoring its long-term effects and to compare its performance with existing therapies in diverse populations. The approval of Vadadustat also demonstrates the changing picture of anemia therapy in CKD. As researchers continue to investigate the biology of CKD-related anemia, innovative therapeutics addressing various elements of the disorder are likely. Other HIF-PHIs are being investigated to provide more personalized patient care[10]. Furthermore, including Vadadustat in current treatment regimens will necessitate extensive recommendations and instruction for healthcare providers. The 2015 Japanese Society for Dialysis Therapy guidelines stress customized treatment options for renal anemia, taking into account patient-specific characteristics such as iron status, inflammation, and comorbidities. Recommendations should position Vadadustat as a first-line oral treatment option, particularly for patients intolerant to or inadequately responding to traditional erythropoiesis-stimulating agents (ESAs). Additionally, the guidelines could emphasize the importance of regular monitoring of hemoglobin levels and blood pressure, as hypertension is a notable adverse effect associated with Vadadustat. Developing clear protocols for transitioning patients from ESAs to Vadadustat would also be beneficial, providing clinicians with actionable stjpg to optimize patient outcomes. Addressing the potential limitations associated with Vadadustat is essential for a comprehensive evaluation of its use in CKD. Notably, drug interactions pose a concern; although Vadadustat primarily undergoes metabolism through UDP-glucuronosyltransferase (UGT) enzymes, with minimal cytochrome P450 involvement, patients on multiple medications may still face complexities that require vigilant monitoring. Patient tolerability can also vary, especially in those with advanced CKD, which may necessitate dose adjustments to achieve optimal therapeutic outcomes. Furthermore, patients with overdose may experience elevated hemoglobin levels, leading to secondary polycythemia, which can complicate clinical management. Finally, the pharmacokinetics of Vadadustat in dialysis-dependent patients indicate a half-life of approximately 9.2 hours, highlighting the importance of understanding its reabsorption dynamics to prevent potential complications. These factors underscore the need for careful patient selection and management to mitigate risks associated with Vadadustat therapy. In summary, the FDA’s approval of Vadadustat represents a significant advancement in the management of anemia in patients with CKD, especially those undergoing dialysis. Alternatives to conventional ESAs may be advantageous due to the novel mode of action, beneficial safety profile, and oral administration. Nevertheless, additional investigation and empirical evidence will be necessary to completely comprehend its long-term implications and economic viability. As we proceed with this new paradigm, continued cooperation between researchers, clinicians, and policymakers will be essential to guarantee the successful integration of Vadadustat and other comparable innovations into clinical practice, thereby enhancing the quality of life for millions of patients with CKD globally.
No takes yet. Share an insight, caveat, or question.
Gul et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: